| Abstract: |
The use of dose-dense therapy is one approach to overcoming the 'resistance' of malignant cells to adjuvant therapy caused by inadequate drug exposure. In this approach, active drugs are delivered sequentially at their 'ideal' dose level separated by short intertreatment intervals. Thus, dose intensification is achieved by means of rapidly recycled treatments rather than by dramatic dose escalation. To overcome absolute cellular resistance, the addition of new, active, non-cross-resistant drugs holds great promise and has specifically motivated the testing of the taxanes. This article describes the results of clinical trials of dose-dense therapy, with particular emphasis on attempts to incorporate one taxane, paclitaxel (Taxol), into the dose-dense regimen of sequential doxorubucin and cyclophosphamide - the so-called A → T → C regimen, and into more conventional regimens. |
| Keywords: |
adult; clinical article; clinical trial; cancer recurrence; doxorubicin; fluorouracil; dose response; conference paper; paclitaxel; adjuvant therapy; chemotherapy, adjuvant; methotrexate; follow up; prospective studies; breast cancer; antimetabolites, antineoplastic; antineoplastic combined chemotherapy protocols; antineoplastic agents, phytogenic; cyclophosphamide; dose-response relationship, drug; breast neoplasms; docetaxel; drug therapy, combination; cancer control; antibiotics, antineoplastic; cell killing; drug exposure; humans; human; female
|
